** Shares of drugmaker Eyenovia EYEN.O rise 6.1% to 11
cents premarket
** EYEN says it will take additional actions to reduce
ongoing personnel-related costs by more than 70%
** Co adds investment firm Avenue Capital has agreed to
restructure loan agreement and delay EYEN's debt repayments,
including principal and interest, until February 2025
** As of Nov. 19, EYEN owed $10.1 million in principal and
accrued interest under the agreement with Avenue Capital,
according to a regulatory filing earlier this week
** EYEN had 57 full-time employees as of March 15, according
to its latest annual report
** Co has been evaluating alternatives after its
experimental drug-device combination for an eye disease failed
in a late-stage study earlier this month
** As of last close, stock had fallen ~95% YTD
(Reporting by Kamal Choudhury in Bangalore)
((Kamal.Choudhury@thomsonreuters.com;))